Parkinson disease (PD) is the second most common neurodegenerative disease, affecting 1% of the population older than 65 years.
1 Slowing PD progression remains a major unmet need.
2 Nilotinib, an approved therapy for chronic myeloid leukemia, works predominantly via BCR-Abelson tyrosine kinase (c-Abl) inhibition. It is neuroprotective in animal models of PD,
3-5 leading to an interest in its development to slow PD progression. However, nilotinib has safety and tolerability liability.
6 At the time of the study launch, the clinical experience with nilotinib in PD was limited to a small study,
7 warranting further careful investigation. Since then, results of a phase 2 study,
8 undertaken by the same group, were reported in 2020 where nilotinib showed acceptable safety and tolerability in moderately advanced PD and favorable changes in exploratory biomarkers of PD pathophysiology without significant effects on clinical outcomes. The primary objective of this multicenter study was to assess safety and tolerability of nilotinib in participants, with moderately advanced PD with secondary and exploratory outcomes, respectively, of effect on PD disability, pharmacokinetics, and biomarkers’ assessment.